


# Legal and policy framework Central and Eastern Europe

**G.Lazdane, RA RHR**  
**WHO Regional Office for Europe**

# Abortion Legislation in Europe (2004)



280500 +Abortions per 1000 live births



# The goal of the Strategy is

**to support Member States in their efforts:**


- to ensure sexual and reproductive rights
- to substantially improve the SRH status of the people
- to reduce the gap in SRH status in WE vs CEE
- to reduce inequities in SRH within European countries

# The right to:

- **Life, survival, security, and sexuality**
- **Reproductive self-determination and free choice of maternity**
- **Health and the benefits of scientific progress**
- **Non-discrimination and due respect for difference**
- **Information, education, and decision-making**

# Medical abortion in CCEE

blue - mifepriston only  
grey - mifepriston + misoprostol



# Baltic countries

	Country	Estonia	Latvia	Lithuania
	Availability of MA	Planned to introduce 2004	Under discussion	No
	Mifepristone registered	+	+	-
	Pg registered	+	-	-

# CIS

Country	Russia	Ukraine	AZB, BLR, GEO, UZB
Availability of MA	+	+	±
Mifepriston e registered	+ (Penkrafton)	+	+
Pg registered	-	+ (Mizonjuvel)	-



# CE countries

Country	Bulgaria	Slovakia	Slovenia
Availability of MA	in progress	-	+
Mifepristone registered	in progress	-	-
Pg registered	±	+	+

## Dissemination of guidance

- **Distribution** to Regional Offices, Ministries of Health, international partner agencies, professional associations, other NGOs
- Combine with **Strategic Approach**
- Include in **Implementing Best Practices** workshops
- Use as a basis for **policy dialogue**
- Use as basis for **elaborating national norms and standards**

# Conclusions - CCEE

- Traditional approach
- “Western” influence
- Strong opposition
- Society is not informed and has no experience of active involvement
- Many countries – small market
- Problem in off-label use of Misoprostol